公开(公告)号：US20240199535A1

公开(公告)日：2024-06-20

申请号：US18554365

申请日：2022-04-08

申请人： IMMUNIC AG

发明人： Christian GEGE ,  Hella KOHLHOF ,  Andreas MÜHLER ,  Daniel VITT

IPC分类号： C07C233/75 ,  A61K31/16 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/472 ,  A61K31/5375 ,  A61P31/14 ,  C07C233/74 ,  C07D213/68 ,  C07D213/73 ,  C07D217/04 ,  C07D265/30 ,  C07D277/34 ,  C07D307/30 ,  C07D333/40 ,  C07D471/04

CPC分类号： C07C233/75 ,  A61K31/16 ,  A61K31/167 ,  A61K31/341 ,  A61K31/381 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/472 ,  A61K31/5375 ,  A61P31/14 ,  C07C233/74 ,  C07D213/68 ,  C07D213/73 ,  C07D217/04 ,  C07D265/30 ,  C07D277/34 ,  C07D307/30 ,  C07D333/40 ,  C07D471/04

摘要： The invention relates to novel deuterated compounds of Formula (I)




and their use as medicaments.

公开(公告)号：US20230152691A1

公开(公告)日：2023-05-18

申请号：US17821820

申请日：2022-08-24

申请人： SUMITOMO CHEMICAL COMPANY, LIMITED

发明人： Katsuhiro KOMURO ,  Saki KATO ,  Koji ICHIKAWA

IPC分类号： G03F7/004 ,  C07D307/68 ,  C07D307/00 ,  C07D307/56 ,  C07D321/10 ,  C07D333/40 ,  C07D333/28

CPC分类号： G03F7/0045 ,  C07D307/68 ,  C07D307/00 ,  C07D307/56 ,  C07D321/10 ,  C07D333/40 ,  C07D333/28

摘要： Disclosed are a salt represented by formula (I), an acid generator, and a resist composition including the same:




wherein R4 to R9 each represent a halogen atom, a haloalkyl group, etc., A1, A2 and A3 each represent a hydrocarbon group, the group may have a substituent, —CH2— in the group may be replaced by —O—, —CO—, —S—, etc., X4, X5 and X6 each represent —O— or —S—, m1 represents an integer of 1 to 5, m2, m3, m8 and m9 represent an integer of 0 to 5, m4, m5 and m6 represent an integer of 0 to 3, m7 represents an integer of 0 to 4, 1≤m1+m7≤5, 0≤m2+m8≤5, 0≤m3+m9≤5, and AI− represents an organic anion.

公开(公告)号：US11618748B2

公开(公告)日：2023-04-04

申请号：US17243272

申请日：2021-04-28

申请人： Aerie Pharmaceuticals, Inc.

发明人： Mitchell A. deLong ,  Jill Marie Sturdivant ,  Susan M. Royalty

IPC分类号： C07D417/12 ,  C07C237/20 ,  C07D401/12 ,  C07D409/12 ,  C07D217/00 ,  C07C237/42 ,  C07D333/40 ,  C07D217/04 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D405/12 ,  C07D413/12 ,  C07D333/38

摘要： Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

公开(公告)号：US20220298173A1

公开(公告)日：2022-09-22

申请号：US17579457

申请日：2022-01-19

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Roland Gendron ,  Melissa Fleury ,  Adam D. Hughes

IPC分类号： C07D498/08 ,  C07D213/81 ,  C07D231/14 ,  C07D233/26 ,  C07D233/90 ,  C07D237/24 ,  C07D239/34 ,  C07D241/24 ,  C07D249/04 ,  C07D249/10 ,  C07D249/18 ,  C07D257/04 ,  C07D261/20 ,  C07D263/34 ,  C07D271/06 ,  C07D277/56 ,  C07D307/68 ,  C07D333/70 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/12 ,  C07D409/06 ,  C07D471/04 ,  C07D498/04 ,  C07D261/18 ,  C07D207/34 ,  C07D239/36 ,  C07D413/06 ,  A61K31/42 ,  A61K31/422 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D413/12 ,  C07D213/79 ,  C07D213/80 ,  C07D237/04 ,  C07D249/08 ,  C07D249/12 ,  C07D261/12 ,  C07D263/56 ,  C07D277/46 ,  C07D333/40

摘要： In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

公开(公告)号：US11261197B2

公开(公告)日：2022-03-01

申请号：US16947214

申请日：2020-07-23

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Roland Gendron ,  Melissa Fleury ,  Adam D. Hughes

IPC分类号： C07D498/08 ,  C07D213/81 ,  C07D231/14 ,  C07D233/26 ,  C07D233/90 ,  C07D237/24 ,  C07D239/34 ,  C07D241/24 ,  C07D249/04 ,  C07D249/10 ,  C07D249/18 ,  C07D257/04 ,  C07D261/20 ,  C07D263/34 ,  C07D271/06 ,  C07D277/56 ,  C07D307/68 ,  C07D333/70 ,  C07D401/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/12 ,  C07D409/06 ,  C07D471/04 ,  C07D498/04 ,  C07D261/18 ,  C07D207/34 ,  C07D239/36 ,  C07D413/06 ,  A61K31/42 ,  A61K31/422 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D413/12 ,  C07D213/79 ,  C07D213/80 ,  C07D237/04 ,  C07D249/08 ,  C07D249/12 ,  C07D261/12 ,  C07D263/56 ,  C07D277/46 ,  C07D333/40

摘要： In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

公开(公告)号：US20200085957A1

公开(公告)日：2020-03-19

申请号：US16460812

申请日：2019-07-02

申请人： Nitto Denko Corporation

发明人： Joseph E. Payne ,  John A. Gaudette ,  Zheng Hou ,  Mohammad Ahmadian ,  Lei Yu ,  Victor Knopov ,  Violetta Akopian ,  Priya Karmali ,  Richard P. Witte ,  Neda Safarzadeh ,  Wenbin Ying ,  Jun Zhang

IPC分类号： A61K47/20 ,  C07C323/60 ,  C07D333/38 ,  C07C271/16 ,  C07D333/40 ,  C07C317/44 ,  C07C333/04 ,  C07C235/08 ,  C07C237/08 ,  C07D207/16 ,  A61K47/14 ,  A61K9/127 ,  A61K47/18 ,  A61K47/22 ,  C07C237/16

摘要： The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

公开(公告)号：US10538503B2

公开(公告)日：2020-01-21

申请号：US16342086

申请日：2017-10-24

申请人： ISHIHARA SANGYO KAISHA, LTD.

发明人： Tatsunori Yoshida

IPC分类号： C07D333/38 ,  C07D333/40

摘要： To provide a method for producing 3-methyl-2-thiophenecarboxylic acid.A method for producing 3-methyl-2-thiophenecarboxylic acid, which comprises reacting 3-methylthiophene with chlorosulfonyl isocyanate, and hydrolyzing the obtained reaction product.

公开(公告)号：US20200002324A1

公开(公告)日：2020-01-02

申请号：US16435254

申请日：2019-06-07

申请人： Aerie Pharmaceuticals, Inc.

发明人： Mitchell A. deLong ,  Jill Marie Sturdivant ,  Susan M. Royalty

IPC分类号： C07D417/12 ,  C07C237/20 ,  C07D401/12 ,  C07D409/12 ,  C07D217/00 ,  C07C237/42 ,  C07D333/40 ,  C07D217/04 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D405/12 ,  C07D413/12 ,  C07D333/38

摘要： Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

公开(公告)号：US20190315735A1

公开(公告)日：2019-10-17

申请号：US16455359

申请日：2019-06-27

申请人： Takeda Pharmaceutical Company Limited

发明人： Shigemitsu MATSUMOTO ,  Yasushi HATTORI ,  Masashi TOYOFUKU ,  Shinji MORIMOTO ,  Masaki DAINI ,  Takuto KOJIMA ,  Tomohiro KAKU ,  Mitsuhiro ITO

IPC分类号： C07D417/14 ,  C07D333/38 ,  C07D413/14 ,  C07D407/12 ,  C07D307/79 ,  C07D409/12 ,  C07D417/12 ,  C07D307/81 ,  C07D413/12 ,  C07D409/14 ,  C07D231/12 ,  C07D277/56 ,  C07D285/135 ,  C07D285/08 ,  C07D333/40 ,  C07D231/14 ,  C07D213/82

摘要： The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US10336773B2

公开(公告)日：2019-07-02

申请号：US15806680

申请日：2017-11-08

申请人： THERAVANCE BIOPHARMA R&D IP, LLC

发明人： Roland Gendron ,  Adam D. Hughes

IPC分类号： C07D498/08 ,  C07D249/08 ,  C07D263/56 ,  C07D233/26 ,  C07D233/90 ,  C07D237/24 ,  C07D249/18 ,  C07D261/18 ,  C07D263/34 ,  C07D271/06 ,  C07D277/56 ,  C07D333/70 ,  C07D401/06 ,  C07D403/06 ,  C07D409/06 ,  C07D498/04 ,  C07D239/36 ,  C07D413/06 ,  A61K31/42 ,  C07D231/14 ,  C07D213/81 ,  C07D239/34 ,  C07D241/24 ,  C07D249/04 ,  C07D249/10 ,  C07D257/04 ,  C07D261/20 ,  C07D307/68 ,  C07D401/04 ,  C07D403/04 ,  C07D405/12 ,  C07D471/04 ,  C07D207/34 ,  A61K31/422 ,  A61K31/5377 ,  A61K45/06 ,  C07D413/04 ,  C07D413/12 ,  C07D213/79 ,  C07D213/80 ,  C07D237/04 ,  C07D249/12 ,  C07D261/12 ,  C07D277/46 ,  C07D333/40

摘要： In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.